What was CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s revenue in fiscal 2025?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B for fiscal 2025, down 0.9% from fiscal 2024.

What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s net margin?

Operating margin was 0.6% and net margin was -3.6%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s diluted EPS?

Diluted EPS was -$2.91, down 1555.0% from the prior year.

Are CHARLES RIVER LABORATORIES INTERNATIONAL, INC. insiders buying or selling shares?

Over the past 12 months, insiders reported 2 open-market purchases totalling $7.3K and 19 open-market sales totalling $43.3M on Form 4.

Which institutions hold CHARLES RIVER LABORATORIES INTERNATIONAL, INC. stock?

898 institutions reported holding CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Overview

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CRLNYSEHealth CareServices-Commercial Physical & Biological ResearchCIK 0001100682Large-cap benchmark

Latest 10-K: FY2025, filed Feb 18, 2026 · Open the 10-K (Inline XBRL) ↗

Ask about CRL in Workspace

Revenue: $4.02B; 0.9%YoYdown from FY2024; TotalRevenue
Gross profit: Not reported
Operating income: $0.03B; 88.9%YoYdown from FY2024; OperatingIncome
Net income: -$0.14B; 750.1%YoYdown from FY2024; NetIncome
Diluted EPS: -$2.91; 1555.0%YoYdown from FY2024; EPSDiluted
Diluted shares: 49.6M; 4.0%YoYdown from FY2024; WeightedAvgSharesDiluted

At a glance

Growth

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B for fiscal 2025, down 0.9% from fiscal 2024.
Revenue grew faster than the median S&P 500 member in 2 of the last 5 fiscal years.

Profitability

Operating margin was 0.6% and net margin was -3.6%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.

Per share

Diluted EPS was -$2.91, down 1555.0% from the prior year.

Insiders & holders

Over the past 12 months, insiders reported 2 open-market purchases totalling $7.3K and 19 open-market sales totalling $43.3M on Form 4.
898 institutions reported holding CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Written from the filed figures on this page by fixed rules — no AI.

Data as of Oct 30, 2026 · Sources: SEC EDGAR 10-K, Form 4, 13F

Quick answers

What was CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s revenue in fiscal 2025?: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B for fiscal 2025, down 0.9% from fiscal 2024.
What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s net margin?: Operating margin was 0.6% and net margin was -3.6%, against a median net margin of 12.8% across S&P 500 members for the same fiscal year.
What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s diluted EPS?: Diluted EPS was -$2.91, down 1555.0% from the prior year.
Are CHARLES RIVER LABORATORIES INTERNATIONAL, INC. insiders buying or selling shares?: Over the past 12 months, insiders reported 2 open-market purchases totalling $7.3K and 19 open-market sales totalling $43.3M on Form 4.
Which institutions hold CHARLES RIVER LABORATORIES INTERNATIONAL, INC. stock?: 898 institutions reported holding CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shares in 13F filings for the quarter ended June 30, 2026; the largest reported position was Abigail P. Johnson's.

Data as of Oct 30, 2026 · Sources: SEC EDGAR 10-K

Financial statements

Annual figures from the 10-K, most recent fiscal year first.

Income Statement

5 annual periods

Chip: YoY change.

Income Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Revenue	$4.02B0.9%down Benchmark median 6.4%	$4.05B1.9%down Benchmark median 4.5%	$4.13B3.9%up Benchmark median 4.8%	$3.98B12.3%up Benchmark median 10.3%	$3.54B21.1%up Benchmark median 13.8%	3.2% Benchmark median 6.6%
Gross Profit Median of 315 / 498	—	—	—	—	—	— Benchmark median 6.2%
Operating Income Median of 373 / 498	$25.16M88.9%down Benchmark median 7.3%	$227.35M63.2%down Benchmark median 7.4%	$617.26M5.2%down Benchmark median 4.9%	$650.98M10.4%up Benchmark median 7.5%	$589.86M36.3%up Benchmark median 23.5%	-54.6% Benchmark median 7.2%
Net Income	negative: -$144.34M750.1%down Benchmark median 4.8%	$22.20M95.3%down Benchmark median 5.7%	$474.62M2.4%down Benchmark median 1.9%	$486.23M24.4%up Benchmark median 1.3%	$390.98M7.3%up Benchmark median 33.9%	n/m Benchmark median 4.1%
EPS (Diluted)	negative: -$2.911555.0%down Benchmark median 6.2%	$0.2097.8%down Benchmark median 7.9%	$9.222.7%down Benchmark median 1.9%	$9.4824.7%up Benchmark median 1.5%	$7.605.6%up Benchmark median 34.8%	n/m Benchmark median 5.6%

Balance Sheet

5 annual periods

Chip: YoY change.

Balance Sheet, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Total Assets	$7.14B5.2%down Benchmark median 5.6%	$7.53B8.1%down Benchmark median 3.4%	$8.20B7.8%up Benchmark median 4.1%	$7.60B8.2%up Benchmark median 2.2%	$7.02B27.9%up Benchmark median 6.7%	0.4% Benchmark median 4.7%
Total Liabilities Median of 357 / 498	$3.92B2.4%down Benchmark median 6.4%	$4.02B11.4%down Benchmark median 1.9%	$4.54B0.9%down Benchmark median 2.9%	$4.58B3.3%up Benchmark median 2.0%	$4.43B32.4%up Benchmark median 5.2%	-3.0% Benchmark median 4.4%
Stockholders' Equity	$3.17B8.6%down Benchmark median 6.8%	$3.47B3.8%down Benchmark median 5.4%	$3.60B20.8%up Benchmark median 7.3%	$2.98B17.4%up Benchmark median 2.5%	$2.54B19.9%up Benchmark median 9.0%	5.7% Benchmark median 6.1%
Cash & Equivalents	$213.77M9.8%up Benchmark median 5.2%	$194.61M29.7%down Benchmark median 1.9%	$276.77M18.3%up Benchmark median 6.7%	$233.91M3.0%down Benchmark median -8.6%	$241.21M5.6%up Benchmark median -2.9%	-3.0% Benchmark median 2.0%
Total Debt	$2.14B4.6%down Benchmark median 2.1%	$2.24B15.5%down Benchmark median 0.2%	$2.65B2.2%down Benchmark median 0.3%	$2.71B1.7%up Benchmark median 0.1%	$2.66B34.7%up Benchmark median -0.1%	-5.4% Benchmark median 4.3%

Cash Flow Statement

5 annual periods

Chip: YoY change.

Cash Flow Statement, annual, newest fiscal year first. 4Y CAGR: compound annual growth from the oldest to the newest year shown. Muted line: large-cap benchmark median change. Line under a label: how many large-cap benchmark companies its median rests on.
Line item	FY2025	FY2024	FY2023	FY2022	FY2021	4Y CAGR
Operating Cash Flow	$737.65M0.4%up Benchmark median 6.3%	$734.58M7.4%up Benchmark median 4.8%	$683.90M10.4%up Benchmark median 9.9%	$619.64M18.6%down Benchmark median -0.7%	$760.80M39.2%up Benchmark median 10.7%	-0.8% Benchmark median 7.0%
Capital Expenditures	$219.15M5.9%down Benchmark median 5.4%	$232.97M26.9%down Benchmark median 2.8%	$318.53M1.9%down Benchmark median 11.3%	$324.73M41.9%up Benchmark median 14.0%	$228.77M37.4%up Benchmark median 8.1%	-1.1% Benchmark median 9.0%
Free Cash Flow Median of 378 / 498	$518.49M3.4%up Benchmark median 7.3%	$501.61M37.3%up Benchmark median 6.1%	$365.37M23.9%up Benchmark median 8.8%	$294.91M44.6%down Benchmark median -11.3%	$532.03M40.0%up Benchmark median 10.2%	-0.6% Benchmark median 4.9%

n/m: not meaningful — the base (the prior year, or the first year for the CAGR) was zero or negative, or a per-share figure’s share basis changed (stock split). “—” means the figure is not available.

Benchmark median = median of the companies in the benchmark universe on Dec 31 of each fiscal year, from their own 10-K filings; a change counts only companies whose prior year was positive. Each median uses every member that reports the line item; where fewer than 80% do (banks and insurers file no gross profit), the row names how many. Published where at least 250 companies report it. Updated 2026-10-27. This compares reported figures, not share-price returns. Methodology

Ratios & valuation

FY2025

Every ratio read two ways: Wall Street’s popular formula and the value investor’s stricter one. Same question, same unit. Pick a ratio.

Valuation · Earnings yield

What a dollar of market value earned

n/m

Wall Street

on net earnings

FY2024 0.1%

5.1%

Value investor

on free cash flow

FY2024 5.2%

How it’s calculated

Wall Street · on net earnings

Diluted EPS ÷ fiscal-year-end share price (1 ÷ P/E)

pe_ratio (ratio table)

P/E n/m

Value investor · on free cash flow

(Operating cash flow − capital expenditures) ÷ market capitalisation (fiscal-year-end close × weighted-average diluted shares)

free cash flow ÷ market cap

Each ratio measures one thing two ways, in the same unit: the popular formula, then a stricter one, so a lower figure is the stricter reading. Gap = value-investor figure minus Wall Street figure, from the figures shown.

Price-based ratios use the fiscal-year-end closing price. Free cash flow = operating cash flow − capital expenditures (we compute it; filings rarely report it). n/m = not meaningful (denominator ≤ 0); “—” = not reported. Each ratio’s formulas are under “How it’s calculated”.

Cash & capital allocation

Where the cash went in FY2025, from the 10-K cash flow statement.

Operating cash flow: $737.65M
Capex: $219.15M
Free cash flow: $518.49M
R&D: —
Buybacks: $360.67M
Dividends: —
Debt repaid: $1.35B
Debt issued: $1.23B
Net debt change: -$121.78M

Uses of operating cash flow, FY2025

Buybacks48.9%
Capex29.7%
Debt repayment182.9%

Each use is shown against operating cash flow on its own; the uses overlap.

Free cash flow by year

FY21$532.03M
FY22$294.91M
FY23$365.37M
FY24$501.61M
FY25$518.49M

Buybacks by year

FY21$40.71M
FY22$38.65M
FY23$24.16M
FY24$119.17M
FY25$360.67M

Smart money

Who is trading and holding CHARLES RIVER LABORATORIES INTERNATIONAL, INC., from Form 4, 13F and 13D/13G filings.

Insiders

Insider activity · past 12 months

Open-market trades reported on Form 4 in the past 365 days.

Buys: 2; 2 insiders
Sales: 19; 6 insiders
Value sold: $43.3M
Shares sold: 168,146
Net shares: -168,111; bought minus sold
Last trade: Oct 21, 2026

Purchases 0% of valueSales 100% of value

Latest open-market insider trades from Form 4
Insider	Type	Date	Shares	Price	Value	Filing
Parisotto Shannon MCEVP, Disc & Safety Assessment	Sell	Oct 21, 2026	2,156	$344.41	$742,548	View filing on SEC EDGAR
Coleman GlennEVP & Chief Financial Officer	Buy	Sep 30, 2026	10	$297.43	$2,974	View filing on SEC EDGAR
FOSTER JAMES CDirector	Sell	Aug 25, 2026	33,561	$300.00	$10,068,300	View filing on SEC EDGAR

See plans

Open-market purchases (code P) and sales (code S) only. Grants, option exercises and tax withholding are excluded. Sales may be made under pre-arranged Rule 10b5-1 plans.

Ownership

Largest institutional holders

13F

Quarter ended Jun 30, 2026; change versus Mar 31, 2026.

Institutions reporting: 898
Top 3 hold: 17.4%; of 49.56M diluted shares, FY2025 10-K

Top 3 holders, share of diluted sharesof 100%

Abigail P. Johnson6.6%
3,251,247 sh · $737.4MAdded 3213.0%13F-HR · Jun 30, 2026 on SEC EDGAR
Vanguard Capital Management6.4%
3,149,288 sh · $714.2MTrimmed 1.7%13F-HR · Jun 30, 2026 on SEC EDGAR
HARRIS ASSOCIATES L P4.5%
2,241,144 sh · $508.3MAdded 4.1%13F-HR · Jun 30, 2026 on SEC EDGAR

See plans

Some filers' amendments could not be read, so a few holders may be counted twice.

Bars: share of diluted shares on a shared scale; the tick marks 5%. 13F filings are due 45 days after quarter end, so this is the latest fully reported quarter. Amended filings are counted once.

Blockholders, 5% and over

13D/G

SC 13D / 13G, latest filing per filer.

Filers at 5%+: 6
Combined: 44.5%; sum of latest filings
Activist (13D): 0

5%+ filers, share of the class as filedof 100%

FMR LLC10.2%
Passive · 13GSC 13G/A · Sep 8, 2026 on SEC EDGAR
Vanguard Capital Management7.38%
Passive · 13GSC 13G · Apr 29, 2026 on SEC EDGAR
Wellington Group Holdings LLP7.25%
Passive · 13GLast filed 1 yr agoSC 13G · Nov 8, 2024 on SEC EDGAR

See plans

No filer switched from a passive 13G to an activist 13D in the last 365 days.

Percent of the class as each filer last reported it; filings older than a year may no longer reflect the stake. Latest filing per filer within three years; a later filing reporting 0% removes the filer.

Full history, every insider and 13F filer, 13D/G activist stakes, and webhooks are on Institutional.

See Institutional

Smart money

Showing the most recent 5 annual periods. Get longer history on the Pro plan, or the full history (1993–present) plus the smart-money dataset and webhooks on Institutional.

Restatement Radar

6 numbers CHARLES RIVER LABORATORIES INTERNATIONAL, INC. later changed — same XBRL tag, both filings linked.

numbers changed: 6
restating filings: 3
came with an amendment or a non-reliance notice: 0

Aug 3, 2011 · 10-Q
changed 2 numbers
No amendment filed
Open filing
- Pretax incomeQ2 2010$20.6M restated to $22.4M+8.6%
  As reported · Aug 3, 2010us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
- Operating incomeQ2 2010$28.2M restated to $30M+6.3%
  As reported · Aug 3, 2010us-gaap:OperatingIncomeLoss
Nov 2, 2011 · 10-Q
changed 3 numbers
No amendment filed
Open filing
- Operating incomeQ3 2010$5.1M restated to $6.5M+26.5%
  As reported · Nov 4, 2010us-gaap:OperatingIncomeLoss
- Pretax incomeQ3 2010-$8.9M restated to -$7.6M+15.2%
  As reported · Nov 4, 2010us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
- Total revenueQ3 2010$276.1M restated to $270.9M−1.9%
  As reported · Nov 4, 2010us-gaap:SalesRevenueNetAny P/S built on the original was 1.9% too low.
Feb 12, 2016 · 10-K
changed 1 number
No amendment filed
Open filing
- Total liabilitiesAs of Dec 27, 2014$1.2B restated to $1.2B−1.2%
  As reported · Feb 17, 2015us-gaap:Liabilities

CRL is not the only one.

See every restatement we've found across the market — or get an alert the next time CRL revises a number.

Restatement Radar Alert me

Restatements are detected by comparing every vintage of a fact across all of CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CRL's most significant revisions, and a figure absent from it has not been certified as unrevised.

Peers, filings & research

Sector Peers

UNITEDHEALTH GROUP INC

MRK· Health Care

Merck & Co., Inc.

TMO· Health Care

THERMO FISHER SCIENTIFIC INC.

ABT· Health Care

ABBOTT LABORATORIES

ISRG· Health Care

INTUITIVE SURGICAL INC

AMGN· Health Care

AMGEN INC

Recent SEC filings

The six newest, periodic reports and 8-Ks together. Dates are SEC filing dates.

All filings on EDGAR

Six most recent SEC filings, newest first
Form	Filing	Filed	Document
8-K	Current report (material events) · Event dated Sep 24, 2026 0001100682-26-000142 · accepted 12:12 UTC	Sep 24, 2026	Open	Filed Sep 24, 2026 · 0001100682-26-000142
8-K	Current report (material events) · Event dated Aug 5, 2026 0001100682-26-000115 · accepted 11:15 UTC	Aug 5, 2026	Open	Filed Aug 5, 2026 · 0001100682-26-000115
10-Q	Quarterly report · Quarter ended Jun 27, 2026 0001100682-26-000118 · accepted 13:21 UTC	Aug 5, 2026	Open	Filed Aug 5, 2026 · 0001100682-26-000118
8-K	Current report (material events) · Event dated May 5, 2026 0000950103-26-007060 · accepted 21:01 UTC	May 11, 2026	Open	Filed May 11, 2026 · 0000950103-26-007060
10-K	Annual report · Fiscal year ended Dec 27, 2025 0001100682-26-000022 · accepted 14:21 UTC	Feb 18, 2026	Open	Filed Feb 18, 2026 · 0001100682-26-000022
10-K/A	Annual report amendment · Fiscal year ended Dec 25, 2004 0001047469-05-006307 · accepted 14:56 UTC	Mar 14, 2005	Open	Filed Mar 14, 2005 · 0001047469-05-006307

“Open” goes to the Inline XBRL viewer when the filing has one, else the primary document. The accession opens the EDGAR index.

Research Reports

No published research on CRL yet.

Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on CRL and publish the result to your public profile.

Browse the research catalog Generate one with your agent

The data behind this page

27 tables, history 1993–present. Every figure above is a row you can query.

Fundamentals

Standardized financial facts, ratios and filings.

fact: 121.4Mrows
ratio: 15.8Mrows
filing: 3.71Mrows
entity: 33,316rows

350+ standard concepts.

Built from these SEC forms

10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QT
10-QT/A
20-F
20-F/A
40-F
40-F/A
8-K
8-K/A
6-K
6-K/A
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-11
S-11/A
F-1
F-1/A
F-3
F-3/A
F-4
F-4/A
POS AM
10-KSB
10-KSB/A
10-QSB
10-QSB/A
DEF 14Asoon
DEF 14Csoon
DEFA14Asoon
PRE 14Asoon
DEFM14Asoon
425soon
SC TO-Tsoon
SC TO-Isoon
SC 14D9soon
SC 13E3soon
CORRESPsoon
NT 10-Ksoon
NT 10-Qsoon
NT 20-Fsoon
N-PORT-Psoon

Smart money

Insider and institutional filings.

institutional_holding: 88.6Mrows
insider_transaction: 12.1Mrows
insider_filing: 5.55Mrows
insider_ownership: 1.98Mrows

109M+ smart-money rows in all.

Built from these SEC forms

Form 3
Form 3/A
Form 4
Form 4/A
Form 5
Form 5/A
13F-HR
13F-HR/A
13F-NT
13F-NT/A
SC 13D
SC 13D/A
SC 13G
SC 13G/A
Form 144
Form 144/A

One real fact row for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Fact receiptOperatingCashFlow

Operating cash flow · FY2025

$0.74B

737,646,000 USD

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Operating cash flow of $737.6M for fiscal year 2025 in its 10-K filed Feb 18, 2026.

Fiscal period: 2025 FY
Period end: 2025-12-27
Form: 10-K
Filed: Feb 18, 2026
Entity (CIK): 0001100682

Provenance trail

Filed with the SEC
Form 10-K, filed Feb 18, 2026.
Accession 0001100682-26-000022
Open in the Inline XBRL viewer for 0001100682-26-000022
Reported in the filing
Operating cash flow for fiscal year 2025, the period ended 2025-12-27, in USD. Valuein maps the filed line to the standard concept OperatingCashFlow.
Stored as one fact row
Every channel returns this row with the same id.
fact_id 4f9c7e1f98b145c86adbcd828e2b360027ad2c3d0388334c46019044d3c8aaad
Shown on this page
The same $0.74B appears in the Cash Flow Statement and in Cash & capital allocation.

fact rowjson

{  "entity_id": "0001100682",  "standard_concept": "OperatingCashFlow",  "fiscal_year": 2025,  "fiscal_period": "FY",  "period_end": "2025-12-27",  "numeric_value": 737646000,  "unit": "USD",  "accession": "0001100682-26-000022",  "fact_id": "4f9c7e1f98b145c86adbcd828e2b360027ad2c3d0388334c46019044d3c8aaad"}

Get the same data

Get your free API key

bash

# Fact-level Parquet over HTTPS, every row traced to its filingcurl -H "Authorization: Bearer $VALUEIN_API_KEY" \  https://data.valuein.biz/v1/pro/fact/0001100682.parquet \  -o crl.parquet

Read the API docs

Terminalbash

# The same tables in your notebooks and backtests; the free sample needs no token$ pip install valuein-sdk

Python

from valuein_sdk import ValueinClient with ValueinClient() as client:    sql = """        SELECT fiscal_year, numeric_value FROM fact        WHERE entity_id = '0001100682'          AND standard_concept = 'TotalRevenue'          AND fiscal_period = 'FY'    """    print(client.run_query(sql))

Install the SDK

bash

# Connect Claude or ChatGPT to the same facts, each with a fact_idhttps://mcp.valuein.biz/mcp Ask your agent:get_company_fundamentals CRL   # CIK 0001100682

Connect the MCP server

bash

# Ask in plain English; every figure comes back cited to its filingTell me about CRL: a quick, cited overview I can dig into.

Open CRL in Workspace

One token unlocks every channel. SDK docs · MCP docs

Cite this page

Data as of Oct 30, 2026. Canonical address: https://valuein.biz/data/CRL

APA-style text

Valuein. (2026, October 30). CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) financial statements, earnings power and smart-money summary [Data set]. Source: SEC EDGAR filings. https://valuein.biz/data/CRL

BibTeX

@misc{valuein_crl_2026,
  author = {{Valuein}},
  title = {CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) financial statements, earnings power and smart-money summary},
  year = {2026},
  howpublished = {\url{https://valuein.biz/data/CRL}},
  note = {Data as of 2026-10-30; source: SEC EDGAR filings}
}

Open 10-K in SEC Inline XBRL viewer

10-K filed Feb 18, 2026 · accession 0001100682-26-000022

Agents: every figure Valuein's tools return carries a fact_id that traces to its SEC filing.

point-in-time · survivorship-free · every number traceable to its SEC filing

View CRL filings on SEC EDGAR

Index names are trademarks of their owners; Valuein is not affiliated with or endorsed by any index provider.

At a glance

Growth

Profitability

Per share

Insiders & holders

02Financial statements

Income Statement

Balance Sheet

Cash Flow Statement

Ratios & valuation

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Smart money

Aug 3, 2011 · 10-Q

Nov 2, 2011 · 10-Q

Feb 12, 2016 · 10-K

06Peers, filings & research

Sector Peers

Recent SEC filings

Research Reports

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Provenance trail

Get the same data

08Cite this page

Insiders & holders

03Cash & capital allocation

Uses of operating cash flow, FY2025

Free cash flow by year

Buybacks by year

04Smart money

Insiders

Insider activity · past 12 months

Ownership

Largest institutional holders

Blockholders, 5% and over

Aug 3, 2011 · 10-Q

Nov 2, 2011 · 10-Q

Feb 12, 2016 · 10-K

Sector Peers

Recent SEC filings

07The data behind this page

Fundamentals

Built from these SEC forms

Smart money

Built from these SEC forms

One real fact row for CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Provenance trail

Get the same data

Financial statements

Cash & capital allocation

Smart money

Peers, filings & research

The data behind this page

Cite this page

Cash & capital allocation

Smart money

The data behind this page